IL323362A - מעכבי קראס - Google Patents
מעכבי קראסInfo
- Publication number
- IL323362A IL323362A IL323362A IL32336225A IL323362A IL 323362 A IL323362 A IL 323362A IL 323362 A IL323362 A IL 323362A IL 32336225 A IL32336225 A IL 32336225A IL 323362 A IL323362 A IL 323362A
- Authority
- IL
- Israel
- Prior art keywords
- carcass
- inhibitors
- carcass inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23382315 | 2023-03-31 | ||
| EP23382531 | 2023-06-02 | ||
| EP23382857 | 2023-08-18 | ||
| EP23382985 | 2023-09-27 | ||
| EP24382267 | 2024-03-12 | ||
| PCT/US2024/022154 WO2024206766A1 (en) | 2023-03-31 | 2024-03-29 | Kras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323362A true IL323362A (he) | 2025-11-01 |
Family
ID=90826251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323362A IL323362A (he) | 2023-03-31 | 2025-09-14 | מעכבי קראס |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240368193A1 (he) |
| JP (2) | JP7669556B2 (he) |
| KR (1) | KR20250163395A (he) |
| CN (1) | CN121002032A (he) |
| AR (1) | AR132295A1 (he) |
| AU (1) | AU2024241889A1 (he) |
| CO (1) | CO2025013134A2 (he) |
| DO (1) | DOP2025000245A (he) |
| IL (1) | IL323362A (he) |
| MX (1) | MX2025011449A (he) |
| WO (1) | WO2024206766A1 (he) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202535880A (zh) * | 2023-10-30 | 2025-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基類化合物、其製備方法及其在醫藥上的應用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10844051B2 (en) | 2015-07-22 | 2020-11-24 | The Royal Institution For The Advancement Of Learning/Mcgill University | Substituted oxazoles for the treatment of cancer |
| EP3710439B1 (en) | 2017-11-15 | 2023-02-15 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW202033518A (zh) | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| JP7622043B2 (ja) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| NZ788613A (en) | 2019-12-11 | 2025-07-25 | Lilly Co Eli | Kras g12c inhibitors |
| CN116390923B (zh) | 2020-08-21 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| CN116368130A (zh) * | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| TWI880049B (zh) | 2020-12-04 | 2025-04-11 | 美商美國禮來大藥廠 | Kras g12c抑制劑 |
| CN115611923A (zh) | 2021-07-12 | 2023-01-17 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN117222654A (zh) | 2021-09-06 | 2023-12-12 | 苏州赞荣医药科技有限公司 | Kras g12c抑制剂和其用途 |
| CN115785199A (zh) | 2021-09-10 | 2023-03-14 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| MX2024011631A (es) * | 2022-03-25 | 2024-09-30 | Lilly Co Eli | Inhibidores de kras. |
-
2024
- 2024-03-29 US US18/621,388 patent/US20240368193A1/en active Pending
- 2024-03-29 CN CN202480023688.7A patent/CN121002032A/zh active Pending
- 2024-03-29 WO PCT/US2024/022154 patent/WO2024206766A1/en active Pending
- 2024-03-29 AU AU2024241889A patent/AU2024241889A1/en active Pending
- 2024-03-29 KR KR1020257035985A patent/KR20250163395A/ko active Pending
- 2024-03-29 JP JP2024055240A patent/JP7669556B2/ja active Active
- 2024-04-03 AR ARP240100807A patent/AR132295A1/es unknown
-
2025
- 2025-04-16 JP JP2025067243A patent/JP2025111535A/ja active Pending
- 2025-09-14 IL IL323362A patent/IL323362A/he unknown
- 2025-09-25 CO CONC2025/0013134A patent/CO2025013134A2/es unknown
- 2025-09-26 MX MX2025011449A patent/MX2025011449A/es unknown
- 2025-09-29 DO DO2025000245A patent/DOP2025000245A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240368193A1 (en) | 2024-11-07 |
| MX2025011449A (es) | 2025-11-03 |
| JP2025111535A (ja) | 2025-07-30 |
| JP2024146897A (ja) | 2024-10-15 |
| KR20250163395A (ko) | 2025-11-20 |
| CN121002032A (zh) | 2025-11-21 |
| DOP2025000245A (es) | 2025-11-16 |
| AU2024241889A1 (en) | 2025-09-25 |
| AR132295A1 (es) | 2025-06-11 |
| TW202506688A (zh) | 2025-02-16 |
| JP7669556B2 (ja) | 2025-04-28 |
| CO2025013134A2 (es) | 2025-10-09 |
| WO2024206766A1 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| IL323362A (he) | מעכבי קראס | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| EP4434979A4 (en) | KIF18A INHIBITOR | |
| IL318420A (he) | מעכבי kras | |
| EP4197538A4 (en) | Egfr inhibitor | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4114375A4 (en) | Ferroptosis inhibitors-diarylamine para-acetamides | |
| EP4499630A4 (en) | BCL-XL INHIBITORS | |
| EP4210694A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4168398A4 (en) | TYK-2 INHIBITOR | |
| EP3976797A4 (en) | ANTI-CRISPR INHIBITORS | |
| EP4405334C0 (en) | Sortilin inhibitors | |
| EP4520976A4 (en) | TURBOCHARGER | |
| EP4448515A4 (en) | PLPRO INHIBITORS | |
| EP4372007A4 (en) | HIF-1 INHIBITOR? | |
| DE112023002022A5 (de) | Isomatte | |
| EP4178620A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4241545C0 (fr) | Bineuse universelle | |
| EP4255426A4 (en) | Y-BOX BINDING PROTEIN 1 INHIBITORS | |
| IL314194A (he) | מעכב tsp1 | |
| AR128365A1 (es) | Inhibidores de parp7 | |
| EP4351574A4 (en) | Inhibitors of ttbk1 | |
| EP4578671A4 (en) | PNEUMATIC | |
| EP4488076A4 (en) | PNEUMATIC |